BioCentury | Mar 11, 2013
Company News

AmorePacific, Brickell Biotech deal

...AmorePacific Corp. (KSE:090430), Seoul, South Korea Brickell Biotech Inc. , Miami, Fla. Business: Dermatology AmorePacific's AmorePacific...
...Brickell did not disclose which compounds AmorePacific has an option to negotiate. Roberts Mitani advised AmorePacific...
...B round in February. Brickell raised an undisclosed amount in the planned $7 million financing. AmorePacific...
BioCentury | Mar 4, 2013
Financial News

Brickell Biotech completes venture financing

...Miami, Fla. Business: Dermatology, Ophthalmic Date completed: 2/26/13 Type: Venture financing Raised: Not disclosed Investors: Amorepacific...
BioCentury | Dec 24, 2012
Financial News

Lithera completes venture financing

...Date completed: 12/19/12 Type: Venture financing Raised: $20.6 million Investors: Rusnano; Domain Associates; Alta Partners; Amorepacific...
BioCentury | Dec 20, 2012
Financial News

Lithera raises $20.6 million

...by Rusnano. Existing investors Domain Associates and Alta Partners also participated, along with new investors Amorepacific...
BioCentury | Dec 22, 2008
Product Development

Taking homework seriously

...with just Celebrex in the U.S. CrystalGenomics licensed CG100649 from AmorePacific Corp. Companies and Institutions Mentioned AmorePacific Corp....
BioCentury | Jun 6, 2005
Product Development

VR1 pipeline

...pain Preclin Renovis/Pfizer Small molecule VR1 antagonists Small molecule VR1 antagonists Pain; urinary incontinence Preclin Schwarz/AmorePacific...
BioCentury | Mar 1, 2004
Strategy

East looks West

...gain access to large markets in the U.S. and Europe. An out-licensing deal by Korea's AmorePacific Corp....
...But Korean biotech is more than human embryonic stem cells, and last week's deal between AmorePacific...
...for an innovative pain treatment," said Antje Witte, spokesperson for Schwarz (FSE:SRZ, Monheim, Germany). "At AmorePacific...
BioCentury | Feb 23, 2004
Company News

Schwarz Pharma, AmorePacific Corp. deal

...Schwarz received exclusive global rights to develop, market and manufacture AmorePacific's PAC20030 vanilloid receptor 1...
...exclude dermatology indications and the territories of Korea and India. PAC20030 is in preclinical development. AmorePacific...
...will receive license fees and is eligible for milestones. Schwarz Pharma AG , Monheim, Germany AmorePacific Corp....
BioCentury | Feb 20, 2004
Company News

Schwarz, AmorePacific pain deal

...Schwarz Pharma (Monheim, Germany) received exclusive global rights to develop, market and manufacture AmorePacific's PAC20030 vanilloid...
...exclude dermatology indications and the territories of Korea and India. PAC20030 is in preclinical development. AmorePacific...
Items per page:
1 - 9 of 9
BioCentury | Mar 11, 2013
Company News

AmorePacific, Brickell Biotech deal

...AmorePacific Corp. (KSE:090430), Seoul, South Korea Brickell Biotech Inc. , Miami, Fla. Business: Dermatology AmorePacific's AmorePacific...
...Brickell did not disclose which compounds AmorePacific has an option to negotiate. Roberts Mitani advised AmorePacific...
...B round in February. Brickell raised an undisclosed amount in the planned $7 million financing. AmorePacific...
BioCentury | Mar 4, 2013
Financial News

Brickell Biotech completes venture financing

...Miami, Fla. Business: Dermatology, Ophthalmic Date completed: 2/26/13 Type: Venture financing Raised: Not disclosed Investors: Amorepacific...
BioCentury | Dec 24, 2012
Financial News

Lithera completes venture financing

...Date completed: 12/19/12 Type: Venture financing Raised: $20.6 million Investors: Rusnano; Domain Associates; Alta Partners; Amorepacific...
BioCentury | Dec 20, 2012
Financial News

Lithera raises $20.6 million

...by Rusnano. Existing investors Domain Associates and Alta Partners also participated, along with new investors Amorepacific...
BioCentury | Dec 22, 2008
Product Development

Taking homework seriously

...with just Celebrex in the U.S. CrystalGenomics licensed CG100649 from AmorePacific Corp. Companies and Institutions Mentioned AmorePacific Corp....
BioCentury | Jun 6, 2005
Product Development

VR1 pipeline

...pain Preclin Renovis/Pfizer Small molecule VR1 antagonists Small molecule VR1 antagonists Pain; urinary incontinence Preclin Schwarz/AmorePacific...
BioCentury | Mar 1, 2004
Strategy

East looks West

...gain access to large markets in the U.S. and Europe. An out-licensing deal by Korea's AmorePacific Corp....
...But Korean biotech is more than human embryonic stem cells, and last week's deal between AmorePacific...
...for an innovative pain treatment," said Antje Witte, spokesperson for Schwarz (FSE:SRZ, Monheim, Germany). "At AmorePacific...
BioCentury | Feb 23, 2004
Company News

Schwarz Pharma, AmorePacific Corp. deal

...Schwarz received exclusive global rights to develop, market and manufacture AmorePacific's PAC20030 vanilloid receptor 1...
...exclude dermatology indications and the territories of Korea and India. PAC20030 is in preclinical development. AmorePacific...
...will receive license fees and is eligible for milestones. Schwarz Pharma AG , Monheim, Germany AmorePacific Corp....
BioCentury | Feb 20, 2004
Company News

Schwarz, AmorePacific pain deal

...Schwarz Pharma (Monheim, Germany) received exclusive global rights to develop, market and manufacture AmorePacific's PAC20030 vanilloid...
...exclude dermatology indications and the territories of Korea and India. PAC20030 is in preclinical development. AmorePacific...
Items per page:
1 - 9 of 9